4 European Projects Found
Searched on 125080 European Projects
FINISHED
Recognising Adverse Drug Reactions (WEB-RADR)
Start date: Sep 1, 2014, End date: Aug 31, 2017,
WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Read Project
20
Partners Participants
FINISHED
Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)
Start date: Sep 1, 2009, End date: Apr 30, 2015,
Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Read Project
36
Partners Participants
FINISHED
Scalable, Standard based Interoperability Framework for Sustainable Pro-active Post Market Safety Studies (SALUS)
Start date: Feb 1, 2012, End date: Apr 30, 2015,
Pre-approval clinical trials cannot possibly ensure that a drug will not have disastrous side effects once it arrives on the market. Post-approval safety data gathering was put in place to address this problem, but as implemented, it has not proven to be as effective as hoped. This is due to the fact that, current post market safety studies largely depend on the submission of spontaneous case repo ...
Read Project
10
Partners Participants
FINISHED
Optimizing drug safety monitoring to enhance patient safety and achieve better health outcomes (Monitoring medicines)
Start date: Sep 1, 2009, End date: Jul 31, 2013,
"Medicines are one of the most common health interventions. Expenditure on pharmaceuticals range from 10–20 % of all health expenditure in rich countries & from 20–60 % in poor countries. Knowledge of appropriate & safe medicines has grown. But the incidence of medicines adverse effects remains high. In a UK study 6.5% of hospitals admissions were related to an adverse drug reaction (ADR). And as ...
Read Project
